NeurAntigen: Autoimmune encephalitis diagnose
Problema a solucionar
Autoimmune encephalitis (AiE) is a severe auto-inflammatory disorder of the brain affecting patients of all ages. Despite being rare, AiE is included among the top differential diagnoses, being it a key step on its treatment with an urgent need for a sensitive and specific test.
Oportunitats de mercat
Current epidemiological studies estimate that the annual incidence of encephalitis of any aetiology is 2-3 patients per 100.000 per year. Given that new autoantibodies are being discovered on a half-yearly basis, the incidence of autoimmune encephalitis is increasing over time and nowadays it is comparable to the infectious aetiology. Autoimmune pathology related drug sales market assumptions in 2019 estimates sales for a total value of $16.2B. By the end of 2027 sales are expected to increase to $24.2B at a Compound Annual Growth Rate (CAGR) of 4.1%. Patent (EP23383041) has been submitted.
Tecnologia
NeurAntigen kit consists of human iPSC-derived neurons, preserved in optimized conditions to be shipped to diagnostic laboratories. Our kit is able to detect all known AiE-related antibodies (14 different antibodies) using non-neural cells as a control through an immunofluorescent Ab-recognition assay in a fast (2 hours) and user-friendly fashion, using patient’s serum or CSF.
Autors
Antonella Consiglio and Eugenia Martínez (H.Clínic)
Technology Readiness Level
TRL5
Què busquem?
Partners for license agreement or co-development